KPTI
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- Karyopharm submitted an sNDA to the FDA for XPOVIO plus ruxolitinib in patients with myelofibrosisAug 31, 2026
- Karyopharm reported topline results from the Phase 3 XPORT-EC-042 trial in endometrial cancerJul 31, 2026
- Karyopharm announced plans to submit an sNDA for selinexor plus ruxolitinib in myelofibrosis under the accelerated approval pathwayJul 31, 2026
- Karyopharm’s Phase 3 SENTRY trial met a co-primary endpoint with significant spleen volume reduction in myelofibrosisMar 24, 2026
- Karyopharm announces completion of enrollment in Phase 3 SENTRY trial in myelofibrosisSep 10, 2025